Status:

COMPLETED

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease

Lead Sponsor:

MedImmune LLC

Conditions:

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

45-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomat...

Detailed Description

A Phase 2 double-blind, placebo-controlled study to evaluate the efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease. The study will have a screening phase of 23 days, treatment phase from W...

Eligibility Criteria

Inclusion

  • Age 45 through 75 years
  • Predicted (Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] stage II, III, and IV) at Screening
  • History of previous acute exacerbations of chronic obstructive pulmonary disease (AECOPD) 12 months prior to Screening
  • Clinically stable and free from an AECOPD for 8 weeks prior to Day 1
  • Current smoker or ex-smoker with a tobacco history of more than or equal to (\>=) 10 pack-years.

Exclusion

  • Past or present disease or disorder,
  • Significant or unstable ischemic heart disease etc
  • Known history of allergy or reaction to any component of the investigational manufacturing product (IMP)
  • Past or current malignancy within the past 5 years
  • Subjects have had a chest x-ray or Computed Tomography (CT) scan suggestive of malignancy or tuberculosis (TB).
  • Use of immunosuppressive medication receipt of any biologic agent.

Key Trial Info

Start Date :

November 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2014

Estimated Enrollment :

464 Patients enrolled

Trial Details

Trial ID

NCT01448850

Start Date

November 1 2011

End Date

February 1 2014

Last Update

January 30 2017

Active Locations (60)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (60 locations)

1

Research Site

Peoria, Arizona, United States

2

Research Site

Clearwater, Florida, United States

3

Research Site

Duluth, Georgia, United States

4

Research Site

Auburn, Maine, United States